Gapping down
Gapping down In reaction to disappointing earnings/guidance: QUIK -31.7%, ADEP -25.5%, IRBT -10.4%, GMCR -9.8%, RSTI -9.2%, LFVN -7.5%, IMMU -7%, AXTI -6.5%, FBHS -6.3%, PMT -6.2%, PRU -4.9%, ATML -4.8%, (announces initial quarterly dividend of $0.04/share), FOXA -4.8%, GEOS -4.8%, KORS -4.4%, NUS -4.2%, GIL -4%, (also announces agreement to acquire Comfort Colors for $100 Million), APO -3.4%, CMI -3.3%, EL -2.8%, ALL -2.7%, (also Increases quarterly dividend ), FMC -2.3%, TDC -2.3%, AZN -2%, PRLB -1.6%, UA -1.5%, (announces the acquisition of Endomondo for $85 mln and MyFitnessPal for $475 mln), BCO -1.5%, CHTR -1.3%, ZUMZ -0.9%, (Zumiez reports Jan same store sales +12.3% vs +6.0% Retail Metrics consensus ), CNW -0.9%
Other news: BIND -5.4% (Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock; details not disclosed, ICPT -3.3% (prices 1 mln shares of its common stock at $176.00 per share), ANTM -3.3% (was victim of cyber attack, according to reports), SABR -3.2% (prices 23.8 mln shares of common stock by existing stockholders affiliated with TPG Global and Silver Lake Management and certain members of Company management at a price of $20.75 per share), MBII -2.9% (Marrone Bio Innovations announces completion of Audit Committee Investigation; update on financial statement review and status of NASDAQ Continued Listing), CASM -2.5% ( intends to offer $8.0 million worth of its common stock in an underwritten public offering), RARE -2.2% (prices 3 mln shares of its common stock at $54.00 per share), NBG -2.1% (Athens stocks down 5% in European trade), XOMA -1.8% (filed for $300 mln mixed securities shelf offering; co also also filed for offering of ~12.1 mln shares of common stock issuable upon the exercise of warrants) PBR -1.2% (confirmed that Fitch Ratings reviewed Petrobras' debt ratings from BBB to BBB-), TKMR -1% ( announces filing of Definitive Proxy Statement and voluntary delisting from the TSX following the agreement and plan of merger and reorganization with OnCore Biopharma)
Analyst comments: NAV -4% (downgraded to Underweight from Overweight at JP Morgan), COST -3% (downgraded to Hold from Buy at Deutsche Bank), RL -1.2% (downgraded to Neutral from Buy at Goldman; downgraded to Neutral from Buy at UBS), M -1% ( downgraded to Equal-Weight from Overweight at Morgan Stanley), ADP -0.7% (downgraded to Market Perform from Outperform at BMO Capital)